Logo image of ATAI

ATAI LIFE SCIENCES NV (ATAI) Stock Fundamental Analysis

USA - NASDAQ:ATAI - NL0015000DX5 - Common Stock

5.375 USD
-0.21 (-3.67%)
Last: 10/9/2025, 3:07:04 PM
Fundamental Rating

3

Overall ATAI gets a fundamental rating of 3 out of 10. We evaluated ATAI against 196 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for ATAI as it has an excellent financial health rating, but there are worries on the profitability. ATAI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ATAI had negative earnings in the past year.
In the past year ATAI has reported a negative cash flow from operations.
ATAI had negative earnings in each of the past 5 years.
In the past 5 years ATAI always reported negative operating cash flow.
ATAI Yearly Net Income VS EBIT VS OCF VS FCFATAI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ATAI (-78.89%) is worse than 71.43% of its industry peers.
Looking at the Return On Equity, with a value of -103.85%, ATAI is doing worse than 60.71% of the companies in the same industry.
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROIC N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ATAI Yearly ROA, ROE, ROICATAI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

ATAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATAI Yearly Profit, Operating, Gross MarginsATAI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -20K -40K -60K

More info and screens

7

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ATAI has more shares outstanding
The number of shares outstanding for ATAI has been increased compared to 5 years ago.
Compared to 1 year ago, ATAI has a worse debt to assets ratio.
ATAI Yearly Shares OutstandingATAI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
ATAI Yearly Total Debt VS Total AssetsATAI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

ATAI has an Altman-Z score of 8.95. This indicates that ATAI is financially healthy and has little risk of bankruptcy at the moment.
ATAI has a better Altman-Z score (8.95) than 84.18% of its industry peers.
There is no outstanding debt for ATAI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.95
ROIC/WACCN/A
WACC7.53%
ATAI Yearly LT Debt VS Equity VS FCFATAI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.02 indicates that ATAI has no problem at all paying its short term obligations.
The Current ratio of ATAI (4.02) is better than 64.29% of its industry peers.
ATAI has a Quick Ratio of 4.02. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.
ATAI's Quick ratio of 4.02 is fine compared to the rest of the industry. ATAI outperforms 65.31% of its industry peers.
Industry RankSector Rank
Current Ratio 4.02
Quick Ratio 4.02
ATAI Yearly Current Assets VS Current LiabilitesATAI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for ATAI have decreased strongly by -72.50% in the last year.
Looking at the last year, ATAI shows a decrease in Revenue. The Revenue has decreased by -1.91% in the last year.
ATAI shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -75.28% yearly.
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%

3.2 Future

ATAI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.45% yearly.
ATAI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 238.35% yearly.
EPS Next Y46.46%
EPS Next 2Y23.13%
EPS Next 3Y13.28%
EPS Next 5Y13.45%
Revenue Next Year339.85%
Revenue Next 2Y-37.82%
Revenue Next 3Y32.02%
Revenue Next 5Y238.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATAI Yearly Revenue VS EstimatesATAI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
ATAI Yearly EPS VS EstimatesATAI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ATAI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATAI Price Earnings VS Forward Price EarningsATAI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATAI Per share dataATAI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as ATAI's earnings are expected to grow with 13.28% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.13%
EPS Next 3Y13.28%

More info and screens

0

5. Dividend

5.1 Amount

ATAI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (10/9/2025, 3:07:04 PM)

5.375

-0.21 (-3.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-14 2025-08-14/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners13.93%
Inst Owner Change0%
Ins Owners2.66%
Ins Owner Change0%
Market Cap1.15B
Analysts84
Price Target11.51 (114.14%)
Short Float %9.12%
Short Ratio2.84
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.25%
Min EPS beat(2)-17.64%
Max EPS beat(2)17.15%
EPS beat(4)1
Avg EPS beat(4)-15.72%
Min EPS beat(4)-62.27%
Max EPS beat(4)17.15%
EPS beat(8)4
Avg EPS beat(8)10%
EPS beat(12)7
Avg EPS beat(12)5.89%
EPS beat(16)9
Avg EPS beat(16)-5.32%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)28.25%
EPS NQ rev (1m)-1.13%
EPS NQ rev (3m)-0.12%
EPS NY rev (1m)-3.98%
EPS NY rev (3m)7.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)6.06%
Revenue NY rev (3m)23.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3740.51
P/FCF N/A
P/OCF N/A
P/B 8.02
P/tB 8.21
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.45
Fwd EYN/A
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS0.67
TBVpS0.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -78.89%
ROE -103.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.42%
ROA(5y)-70.02%
ROE(3y)-67.79%
ROE(5y)-86.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 830.23%
Cap/Sales 2024.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.02
Quick Ratio 4.02
Altman-Z 8.95
F-Score2
WACC7.53%
ROIC/WACCN/A
Cap/Depr(3y)268.35%
Cap/Depr(5y)673.01%
Cap/Sales(3y)220.74%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%61.11%
EPS Next Y46.46%
EPS Next 2Y23.13%
EPS Next 3Y13.28%
EPS Next 5Y13.45%
Revenue 1Y (TTM)-1.91%
Revenue growth 3Y-75.28%
Revenue growth 5YN/A
Sales Q2Q%163.37%
Revenue Next Year339.85%
Revenue Next 2Y-37.82%
Revenue Next 3Y32.02%
Revenue Next 5Y238.35%
EBIT growth 1Y18.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.75%
EBIT Next 3Y-16.28%
EBIT Next 5Y-3.12%
FCF growth 1Y21.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.11%
OCF growth 3YN/A
OCF growth 5YN/A